PharmacoEconomics

2 papers in the last 7 days · category: Health Economics and Policy · publisher: Adis, Springer Healthcare · ISSN 1170-7690

← Papers per journal

Key findings#

PharmacoEconomics published 9 papers in the last 30 days (2026-10-01 to 2026-10-30), ranking #116 of 392 journals.
Leading institutions: Newcastle University (2), University of Maryland, Baltimore (2) and University of Exeter (2).
Countries: United Kingdom (5), United States (3) and United Arab Emirates (1).
From Oct 2023 to Sep 2026, PharmacoEconomics published 342 papers (10 a month on average, by publication date in OpenAlex).
Its most frequent keywords over that period were “cost-effectiveness” (96), “quality-adjusted life years” (80) and “health technology assessment” (75).
Its most-cited paper of the period is “A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist” (2024-09-03), with 121 citations.
Since October 2016, its most-cited paper is “The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)” (2021-05-05), with 839 citations.

The last 36 months#

Oct 23Sep 26

Papers by publication date, Oct 2023 to Sep 2026
Oct 23–Sep 24	Oct 24–Sep 25	Oct 25–Sep 26	36 months
112	111	119	342

Most frequent keywords, Oct 2023 to Sep 2026
#	Keyword	Papers
1	cost-effectiveness	96
2	quality-adjusted life years	80
3	health technology assessment	75
4	economic evaluation	35
5	health-related quality of life	35
6	health care costs	26
7	cost-effectiveness analysis	25
8	Markov model	24
9	cost-utility analysis	21
10	economic burden	19

Most-cited papers published Oct 2023 to Sep 2026
#	Citations	Per month	Title	Journal	Published	Authors
1	121	4.7	A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist	PharmacoEconomics	2024-09-03	Jemimah Ride, Ilias Goranitis, Yan Meng et al.
2	59	1.7	Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force	PharmacoEconomics	2023-12-02	Edward Henry, Hareth Al‐Janabi, Werner B. F. Brouwer et al.
3	39	2.3	The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review	PharmacoEconomics	2025-05-21	Sven P H Nouwens, Stella Maria Marceta, Michael Bui et al.
4	32	1.3	Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach	PharmacoEconomics	2024-10-25	Laura Vallejo‐Torres
5	29	0.8	Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial	PharmacoEconomics	2023-11-10	Junwen Zhou, Claire Williams, Mi Jun Keng et al.

Most-cited since October 2016# All journals →

The journal's most-cited papers published since October 2016
#	Citations	Per month	Title	Journal	Published	Authors
1	839	12.7	The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)	PharmacoEconomics	2021-05-05	Paul E. Greenberg, Andrée-Anne Fournier, Tammy Sisitsky et al.
2	803	8.4	Discrete Choice Experiments in Health Economics: Past, Present and Future	PharmacoEconomics	2018-11-02	Vikas Soekhai, Esther Wilhelmina de Bekker-Grob, Alan R. Ellis et al.
3	592	5.7	German Value Set for the EQ-5D-5L	PharmacoEconomics	2018-02-19	Kristina Ludwig, J.-Matthias Graf von der Schulenburg, Wolfgang Greiner
4	394	5.3	A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)	PharmacoEconomics	2020-08-19	Michael Urbich, Gary A. Globe, Krystallia Pantiri et al.
5	380	3.6	Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries	PharmacoEconomics	2018-02-22	Mathieu F. Janssen, Gouke J. Bonsel, Nan Luo
6	360	5.7	How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment	PharmacoEconomics	2021-08-08	Michael Schlander, K. Hernández-Villafuerte, Chih‐Yuan Cheng et al.
7	355	3.4	A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D	PharmacoEconomics	2018-03-23	Ines Buchholz, Mathieu F. Janssen, Thomas Kohlmann et al.
8	350	3.5	Discounting in Economic Evaluations	PharmacoEconomics	2018-05-19	Arthur E. Attema, Werner B. F. Brouwer, Karl Claxton
9	334	2.9	Discrete Choice Experiments: A Guide to Model Specification, Estimation and Software	PharmacoEconomics	2017-04-03	Emily Lancsar, Denzil G. Fiebig, Arne Risa Hole
10	279	3.7	Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018	PharmacoEconomics	2020-07-22	David D. Kim, Madison C. Silver, Natalia Kunst et al.

Papers, newest first.
Date	Title	Journal	Authors	Affiliations
2026-10-26	Modelling Carer Quality-Adjusted Life-Years Into Economic Evaluations: An Evidence Assessment Group Perspective	PharmacoEconomics	Giovany Orozco-Leal, Louise Tanner, Eugenie Evelynne Johnson et al.	Newcastle University
2026-10-25	Measuring the Health of Young Children	PharmacoEconomics	Daniel M. Hausman	University of Wisconsin–Madison
2026-10-23	Beyond Traditional Cost-Effectiveness Analysis: Operationalizing the Equivalent Income Approach for Equity-Sensitive Health Technology Assessment	PharmacoEconomics	Pauline Chauvin, Clémence Thébaut	Université Paris Cité; Sorbonne University Abu Dhabi; Laboratoire Interdisciplinaire de Recherche Appliquée en Economie-Gestion et Santé; …
2026-10-22	Patient-Centered Value Elements in the Economic Evaluation of Chronic Obstructive Pulmonary Disease (COPD): A Targeted Review of Cost-Effectiveness Analyses	PharmacoEconomics	Nabin Poudel, Leah Lodise, Jiwon Oh et al.	University of Maryland, Baltimore
2026-10-15	The Opportunity Cost of Funding High-Cost Biologics in the Context of Inequitable Access to the Fundamentals of Care: An External Assessment Group Perspective	PharmacoEconomics	Julia C. Whitehall, Louise Tanner, Nawaraj Bhattarai et al.	Newcastle University; Leeds Teaching Hospitals NHS Trust
2026-10-09	Waiting for Trial Evidence or Using Real-World Evidence: Trade-Offs for Coverage with Evidence Development	PharmacoEconomics	Boshen Jiao, Yizhi Liang, 陶立元 et al.	University of Southern California; Peking University; Peking University Third Hospital; …
2026-10-09	Methodological Challenges and Preferred Approaches for the Economic Evaluation of CAR T Therapies: Evidence Review and Expert Consensus from NICE Appraisals	PharmacoEconomics	Mehdi Yousefi, Amin Mehrabian, Maeve A O'Reilly et al.	University of Birmingham; University College Hospital; University of Exeter
2026-10-06	Methods in Systematic Reviews of Health Economic Evaluations in Submissions to Health Technology Assessment Agencies: How Systematic Are They, and Does This Matter?	PharmacoEconomics	Chris Bartlett, Rachael McCool, Matthew J. Taylor	University of York
2026-10-06	Correction: Comparing User‑Written Codes for Performing Economic Evaluations in Stata	PharmacoEconomics	Bradley Barker-Jones, Patricia Navvuga, Petra Baji et al.	University of Bristol; University of Exeter; Southmead Hospital

Cite this page

Scholar4AI. (2026). PharmacoEconomics. Journal Research Rankings. Retrieved October 30, 2026, from https://scholar4ai.com/journals/pharmacoeconomics

@misc{scholar4ai-journals-pharmacoeconomics,
  author = {{Scholar4AI}},
  title = {PharmacoEconomics},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/journals/pharmacoeconomics}},
  urldate = {2026-10-30},
  note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}

Free to reuse for non-commercial purposes with attribution (CC BY-NC 4.0).